Dr. Edith Perez, from the Mayo Clinic Cancer Center, Discusses the BOLERO-2 Everolimus Trial
Edith A. Perez, MD, deputy director, Mayo Clinic Cancer Center, Florida, director, Breast Program, Serene M. and Frances C. Durling Professor of Medicine, Mayo Medical School, discusses the results of the phase III BOLERO-2 trial that examined women with hormone receptor-positive (HR+) metastatic breast cancer that had developed disease progression and resistance to aromatase inhibitors.
The trial enrolled 724 postmenopausal women that had progressed on anastrozole or letrozole. Patients were randomized 2:1 to receive exemestane plus everolimus or exemestane and placebo. The addition of everolimus resulted in a median progression-free survival of 7.4 months compared to 3.2 months in the control arm.
Perez describes the results of the BOLERO-2 trial as unprecedented. The addition of everolimus showed clinical efficacy and offers immense value for patients with refractory estrogen receptor positive metastatic breast cancer.